CPAP对OSA患者代谢综合征的影响:一项随机试验
CPAP组MS逆转率高于安慰剂组(18% vs 4%;OR 5.27;95%CI 1.27-35.86;
要点
- CPAP未显著改善MS各组分、体重、肝脂肪变、血脂、脂联素和瘦素。
- CPAP仅带来内脏脂肪轻微减少和内皮功能改善。
核心结论
- CPAP治疗6个月后MS逆转率高于安慰剂,但多数患者仍保留MS诊断。
- CPAP对脂肪指标和脂肪库缺乏显著或相关效应,支持OSA在调节MS中作用有限。
研究设计与样本
- TREATOSA-MS为随机安慰剂对照试验,纳入新诊断MS且伴中重度OSA(AHI≥15 events/h)的成人。
- 干预为治疗性CPAP或鼻扩张条(安慰剂)6个月,CPAP平均依从性5.5±1.5 h/night。
主要发现
- 二次分析中CPAP未显著降低MS各组分、体重、肝脂肪变、血脂、脂联素和瘦素。
- CPAP促进内脏脂肪非常轻微的减少并改善内皮功能(所有分析均校正基线值)。
临床怎么用
- 对OSA合并MS患者,CPAP可能提高MS逆转概率但不应期望显著改善代谢和脂肪指标。
- CPAP对内脏脂肪和内皮功能的轻微改善可作为综合管理的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: OSA is associated with metabolic syndrome (MS), but it is unclear whether OSA treatment with CPAP can revert MS. RESEARCH QUESTION: Does OSA treatment with CPAP per se have effects on the MS reversibility and the associated metabolic, adiposity and vascular parameters? STUDY DESIGN AND METHODS: The TREATOSA-MS trial is a randomized placebo-controlled trial that enrolled adult patients with a recent diagnosis of MS and moderate or severe OSA (apnea-hypopnea index [AHI], ≥ 15 events/h) to undergo therapeutic CPAP or nasal dilator strips (placebo group) for 6 months. Before and after each intervention, we measured anthropometric variables, BP, glucose, and lipid profile. To control potential-related mechanisms and consequences, we also measured adiposity biomarkers (leptin and adiponectin), body composition, food intake, physical activity, subcutaneous and abdominal fat (visceral and hepatic fat), and endothelial function. RESULTS: One hundred patients (79% men; mean age, 48 ± 9 years; BMI, 33 ± 4 kg/m2; AHI, 58 ± 29 events/h) completed the study (n = 50 per group). The mean CPAP adherence was 5.5 ± 1.5 h/night. After 6 months, most patients with OSA randomized to CPAP retained the MS diagnosis, but the rate of MS reversibility was higher than observed in the placebo group (18% vs 4%; OR, 5.27; 95% CI, 1.27-35.86; P = .04). In the secondary analysis, CPAP did not promote significant reductions in the individual components of MS, weight, hepatic steatosis, lipid profile, adiponectin, and leptin, but did promote a very modest reduction in visceral fat and improved endothelial function (all analyses were adjusted for baseline values). INTERPRETATION: Despite the higher rate of MS reversibility after CPAP therapy as compared with placebo, most patients retained this diagnosis. The lack of significant or relevant effects on adiposity biomarkers and depots supports the modest role of OSA in modulating MS. TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02295202; URL: www. CLINICALTRIALS: gov.
引用
- Giampá SQC, Furlan SF, Freitas LS, et al. Effects of CPAP on Metabolic Syndrome in Patients With OSA: A Randomized Trial. Chest. 2022. PMID: 35063452. doi:10.1016/j.chest.2021.12.669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。